138163-07-2

Usage

Uses

Used in Pharmaceutical Synthesis:
4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique molecular structure allows for the creation of a diverse range of drug candidates with potential therapeutic applications.
Used in Organic Chemistry Reactions:
In the field of organic chemistry, 4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER serves as a valuable building block for the development of complex organic molecules. Its reactivity and structural features facilitate the formation of new chemical entities with potential applications in various industries.
Used in Medicinal Chemistry Research:
4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is utilized as a starting material in medicinal chemistry research for the design and discovery of new therapeutic agents. Its potential biological activity and structural properties make it an attractive candidate for the development of novel drugs with improved efficacy and safety profiles.
Used in Drug Development:
4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is employed in the development of new drugs and bioactive molecules. Its versatility and potential applications in various therapeutic areas make it a promising compound for the creation of innovative pharmaceutical products.
Used in Bioactive Molecule Design:
In the design of bioactive molecules, 4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a structural component to enhance the biological activity and pharmacological properties of these molecules. Its incorporation into the molecular framework can lead to the development of compounds with improved therapeutic potential.
Overall, 4-CARBOXYMETHOXY-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is a multifaceted chemical compound with a broad range of applications in the fields of chemistry and pharmaceutical science. Its unique properties and potential uses make it an indispensable tool for researchers and chemists working towards the advancement of medicine and healthcare.

InChI:InChI=1/C15H19NO4/c1-19-14(17)13-7-9-16(10-8-13)15(18)20-11-12-5-3-2-4-6-12/h2-6,13H,7-11H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 2971-79-1 isonipecotic acid methyl ester 
• 501-53-1 benzyl chloroformate 
• 67-56-1 methanol 
• 286961-24-8 benzyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)-pyridine-1-carboxylate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 498-94-2 isonipecotic acid 
• 7462-86-4 methyl piperidine-4-carboxylate hydrochloride 

Downstream Products

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 940313-20-2 1-Benzyl 4-methyl 4-(2-chloroethyl)piperidine-1, 4-dicarboxylate 
• 940313-32-6 1-benzyl 4-methyl 4-allylpiperidine-1,4-dicarboxylate 
• 161609-84-3 4-cyanopiperidine-1-carboxylic acid benzyl ester 
• 167757-45-1 4-Carbamoylpiperidine-1-carboxylic acid benzyl ester 
• 161609-80-9 benzyl 4-(hydrazinylcarbonyl)piperidine-1-carboxylate 
• 1061683-37-1 benzyl 4-(2-methoxypropan-2-yl)piperidine-1-carboxylate 
• 160809-39-2 1-(benzyloxycarbonyl)-4-(1-hydroxy-1-methylethyl)piperidine 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 1155860-37-9 C₃₂H₃₄Cl₄N₄O₆S₂ 
• 593261-71-3 C₂₀H₂₂Cl₂N₂O₃S 
• 1155860-74-4 C₂₅H₂₅Cl₂N₂OP 
• 1155860-72-2 C₃₄H₃₄Cl₄N₄O₄ 

Relevant academic research and scientific papers

DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER

Present invention relates to novel heterocyclic compounds as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) modulators. Compounds of the present invention inhibit tryptophan degradation by modulating IDO and/or TDO. Formula (I) The invention further relates to the process of their preparation, pharmaceutical composition and their use in modulating the activity of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3- dioxygenase (TDO). The compounds of the invention can be used alone or in combination for the treatment of conditions that benefits from the inhibition of tryptophan degradation.

POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of s

Synthesis of Ketones and Esters from Heteroatom-Functionalized Alkenes by Cobalt-Mediated Hydrogen Atom Transfer

Cobalt bis(acetylacetonate) is shown to mediate hydrogen atom transfer to a broad range of functionalized alkenes; in situ oxidation of the resulting alkylradical intermediates, followed by hydrolysis, provides expedient access to ketones and esters. By modification of the alcohol solvent, different alkyl ester products may be obtained. The method is compatible with a number of functional groups including alkenyl halides, sulfides, triflates, and phosphonates and provides a mild and practical alternative to the Tamao-Fleming oxidation of vinylsilanes and the Arndt-Eistert homologation.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

Substituted Pyrimidine and Triazine Compounds

Substituted pyrimidine and triazine compounds corresponding to formula I wherein R1, R2, R3, R4a, R4b, R5a, R5b, R7, R8, R9a, R9b, R10, R11, A, a, b, s, t, V, W1, W2 and W3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit pain and/or other disorders or disease states.

Substituted Indole Compounds

Substituted indole compounds corresponding to the formula I: In which R8, R9a, R9b, R10, R11, R200, R210, A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

Substituted Spiro-amide Compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES

The present invention relates to substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

Discovery of potent non-urea inhibitors of soluble epoxide hydrolase

Soluble epoxide hydrolase (sEH) is a novel target for the treatment of hypertension and vascular inflammation. A new class of potent non-urea sEH inhibitors was identified via high throughput screening (HTS) and chemical modification. IC50s of the most potent compounds range from micromolar to low nanomolar.